Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO- and PGE-2-dependent pathways [v1; ref status: indexed, http://f1000r.es/x3]
Human mesoangioblasts are currently in a phase I/II clinical trial for the treatment of patients with Duchenne muscular dystrophy. However, limitations associated with the finite life span of these cells combined with the significant numbers of mesoangioblasts required to treat all of the skeletal m...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2013-01-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/2-24/v1 |